Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Brii Biosciences Limited

Healthcare US BRIBF

0.1495USD
0.00(0%)

Last update at 2026-06-19T20:00:00Z

Day Range

0.230.25
LowHigh

52 Week Range

0.180.30
LowHigh

Fundamentals

  • Previous Close 0.15
  • Market Cap166.64M
  • Volume4154
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-284.55600M
  • Revenue TTM35.55M
  • Revenue Per Share TTM0.05
  • Gross Profit TTM 35.55M
  • Diluted EPS TTM-0.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -216.43379M -512.38100M -184.37000M -489.78100M -4191.08400M
Minority interest - 4.22M 9.54M 5.47M 27.23M
Net income -216.87899M -508.16200M -174.82900M -484.31200M -4163.84900M
Selling general administrative - 153.16M 55.69M 53.47M 79.31M
Selling and marketing expenses - 50.79M 1.42M 26.86M -
Gross profit - 49.94M 0.62M 51.63M -
Reconciled depreciation - 8.85M 15.67M 17.03M 14.55M
Ebit -295.90562M -403.85400M -183.87600M -520.61600M -4234.70400M
Ebitda -290.31278M -401.60900M -168.20200M -503.58400M -4217.44200M
Depreciation and amortization 5.59M 2.25M 15.67M 17.03M 17.26M
Non operating income net other - - - - -
Operating income -295.90562M -403.85400M -544.30100M -520.61600M -4234.70400M
Other operating expenses 314.03M 453.79M 545.35M 565.81M 642.61M
Interest expense 1.91M 2.37M 0.49M 0.85M 1.18M
Tax provision - 0.00000M 0.00000M 0.00000M 0.00000M
Interest income - 87.15M 108.02M 37.20M 6.49M
Net interest income - 84.79M 107.53M 36.35M 5.32M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.85M - -1.34422M -5.46900M -27.23500M
Total revenue 18.12M 49.94M 0.62M 51.63M 0.00000M
Total operating expenses 308.44M 453.79M 545.35M 565.81M 642.61M
Cost of revenue - - -55.27400M - -
Total other income expense net 79.47M -108.52700M 359.93M 30.84M 43.62M
Discontinued operations - - - - -
Net income from continuing ops - -512.38100M -184.37000M -489.78100M -4191.08400M
Net income applicable to common shares - - - -484.31200M -4163.84900M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2360.76M 2706.62M 3198.25M 3391.85M 3611.70M
Intangible assets - 179.71M 267.42M 146.89M 9.51M
Earning assets - - - - -
Other current assets 21.54M 93.81M 122.12M 79.52M 7.68M
Total liab 36.22M 100.55M 125.87M 234.35M 300.44M
Total stockholder equity 2376.89M 2656.96M 3119.04M 3194.61M 3342.90M
Deferred long term liab - - - - -
Other current liab 27.29M 71.34M 122.71M 219.61M 271.74M
Common stock 0.02M 0.02M 0.02M 0.02M 0.02M
Capital stock - 0.02M 0.02M 0.02M 0.02M
Retained earnings - -7205.20100M - - -6037.89800M
Other liab - - - 2.08M 7.08M
Good will - - - - -
Other assets - - - 2.51M 2.79M
Cash 608.68M 1003.37M 489.65M 1190.57M 2855.09M
Cash and equivalents - - - - -
Total current liabilities 32.33M 77.42M 125.87M 229.11M 280.71M
Current deferred revenue - - - - -
Net debt -599.74779M -975.34500M -486.49400M -1177.91600M -2833.47700M
Short term debt 5.04M 4.90M 3.16M 9.50M 8.97M
Short long term debt - - - - -
Short long term debt total 8.93M 28.02M 3.16M 12.66M 21.62M
Other stockholder equity 2376.86M 9862.13M - 3194.59M 3342.88M
Property plant equipment - - - 19.52M 33.44M
Total current assets 1963.56M 2414.12M 2782.78M 3076.90M 3413.94M
Long term investments - - - - -
Net tangible assets - - - 3047.73M 3333.40M
Short term investments 1333.34M 1316.95M 2171.01M 1806.81M 499.65M
Net receivables - - - - 51.52M
Long term debt - 17.97M - - -
Inventory - - - - -
Accounts payable - - - - -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - 3119.02M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 77.42M 1406.25M - 1809.33M 502.43M
Deferred long term asset charges - - - - -
Non current assets total 397.20M 292.50M 415.47M 314.95M 197.76M
Capital lease obligations - 10.05M 3.16M 12.66M 21.62M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 895.47M -104.35000M -1433.16800M -479.89500M -44.70900M
Change to liabilities - - 0.00000M -308.55900M 495.47M
Total cashflows from investing activities 895.47M -104.35000M - -475.75600M -43.65000M
Net borrowings - - - -9.74500M -6.78600M
Total cash from financing activities -9.40600M -10.97700M -3.04200M 3230.13M 657.00M
Change to operating activities - - - -25.18300M -24.01900M
Net income -512.38100M -184.37000M -489.78100M -4191.08400M -1283.51000M
Change in cash 513.72M -700.92200M -1664.52100M 1820.13M 154.61M
Begin period cash flow 489.65M 1190.57M 2855.09M 1034.96M 880.36M
End period cash flow 1003.37M 489.65M 1190.57M 2855.09M 1034.96M
Total cash from operating activities -372.89000M -594.01400M -496.27900M -879.45700M -403.71600M
Issuance of capital stock 0.05M 0.18M 7.45M 3327.68M 668.53M
Depreciation 8.85M 15.67M 17.03M 17.26M 14.21M
Other cashflows from investing activities -6.03400M 114.52M - 5.17M 1.06M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock -0.22000M -1.16200M -0.67800M - -
Other cashflows from financing activities -2.36600M -0.49400M -9.81100M 904.90M 656.86M
Change to netincome - - - 3600.87M 300.23M
Capital expenditures 3.23M 49.61M 139.29M 1.03M 1.03M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -50.40900M -120.73300M -76.99400M -333.74200M 471.45M
Stock based compensation 16.05M 64.22M 77.93M 79.37M 29.48M
Other non cash items 165.00M -368.80800M -24.46400M 3548.74M 364.65M
Free cash flow -376.11800M -643.62200M -635.57100M -880.48600M -403.71600M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
BRIBF
Brii Biosciences Limited		 - -% 0.15 - - 4.69 0.39 0.03
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It also develops BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with chronic NTM lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.

Brii Biosciences Limited

Building 7, International Science Park, Beijing, China, 100192

Key Executives

Name Title Year Born
Dr. Zhi Hong Ph.D. Co-founder, Exec. Chairman & CEO 1964
Dr. Ankang Li C.F.A., J.D., Ph.D. Chief Financial & Strategy Officer, Company Sec. and Exec. Director 1978
Dr. Eleanor de Groot Ph.D. Chief Technology Officer 1969
Ms. Karen Del Barrio Neuendorff Chief People Officer & Head of HR NA
Mr. Coy Stout Head of Patient Advocacy NA
Dr. Li Yan M.D., Ph.D. Chief Medical Officer NA
Dr. Lianhong Xu Ph.D. Head of Discovery NA
Dr. Qing Zhu Ph.D. Head of China R&D NA
Dr. David Margolis M.D., M.P.H. VP & Head of Infectious Diseases Therapy Area NA
Dr. Susannah Cantrell Ph.D. Chief Bus. Officer 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.